56.26
price up icon2.01%   1.11
after-market 시간 외 거래: 56.26
loading
전일 마감가:
$55.15
열려 있는:
$55.61
하루 거래량:
681.18K
Relative Volume:
0.80
시가총액:
$3.49B
수익:
$45.48M
순이익/손실:
$169.95M
주가수익비율:
21.47
EPS:
2.62
순현금흐름:
$230.85M
1주 성능:
+1.88%
1개월 성능:
+1.02%
6개월 성능:
+48.09%
1년 성능:
+39.67%
1일 변동 폭
Value
$55.20
$57.10
1주일 범위
Value
$53.02
$57.10
52주 변동 폭
Value
$32.50
$60.60

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Name
명칭
Protagonist Therapeutics Inc
Name
전화
(510) 474-0170
Name
주소
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Name
직원
124
Name
트위터
Name
다음 수익 날짜
2025-05-02
Name
최신 SEC 제출 서류
Name
PTGX's Discussions on Twitter

PTGX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
PTGX
Protagonist Therapeutics Inc
56.26 3.42B 45.48M 169.95M 230.85M 2.62
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
460.83 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.63 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.79 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
595.19 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.51 31.54B 3.81B -644.79M -669.77M -6.24

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-06-17 개시 Citigroup Buy
2024-12-06 개시 BMO Capital Markets Outperform
2024-12-06 개시 Goldman Neutral
2024-11-05 개시 Wedbush Outperform
2024-09-24 개시 TD Cowen Buy
2024-09-09 개시 Truist Buy
2023-10-30 개시 CapitalOne Overweight
2023-05-25 재개 Jefferies Buy
2022-08-25 개시 JMP Securities Mkt Outperform
2022-02-11 개시 BTIG Research Buy
2021-10-12 업그레이드 JP Morgan Neutral → Overweight
2021-10-11 업그레이드 Northland Capital Market Perform → Outperform
2021-09-20 다운그레이드 JP Morgan Overweight → Neutral
2021-05-24 개시 JMP Securities Mkt Outperform
2021-05-24 개시 Northland Capital Outperform
2021-01-06 개시 JP Morgan Overweight
2020-12-16 개시 Piper Sandler Overweight
2020-09-18 재확인 H.C. Wainwright Buy
2020-07-15 개시 Jefferies Buy
2020-05-18 재확인 H.C. Wainwright Buy
2019-07-08 개시 H.C. Wainwright Buy
2019-05-09 업그레이드 Stifel Hold → Buy
2018-12-06 개시 Nomura Buy
2018-01-29 개시 Stifel Buy
2017-07-21 개시 BTIG Research Buy
모두보기

Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스

pulisher
06:35 AM

Protagonist therapeutics CEO Patel sells $570k in stock By Investing.com - Investing.com India

06:35 AM
pulisher
06:32 AM

What is the dividend policy of Protagonist Therapeutics Inc. stockFree Stock Market Return Analysis - jammulinksnews.com

06:32 AM
pulisher
05:48 AM

What are Protagonist Therapeutics Inc. company’s key revenue driversDaily Trading Picks Backed By Experts - jammulinksnews.com

05:48 AM
pulisher
01:49 AM

What catalysts could drive Protagonist Therapeutics Inc. stock higher in 2025Capitalize on trading strategies that deliver - jammulinksnews.com

01:49 AM
pulisher
Jul 27, 2025

What institutional investors are buying Protagonist Therapeutics Inc. stockUnlock exclusive stock market forecasts - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Is Protagonist Therapeutics Inc. a growth stock or a value stockGame-changing returns - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Protagonist Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayShort Squeeze Radar - metal.it

Jul 27, 2025
pulisher
Jul 26, 2025

Does Protagonist Therapeutics Inc. stock pay reliable dividendsFree Consultation - metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

Johnson & Johnson Submits NDA for Protagonist-Partnered Icotrokinra to FDA for Plaque Psoriasis - MSN

Jul 25, 2025
pulisher
Jul 24, 2025

Protagonist Therapeutics Inc. Stock Analysis and ForecastExponentially increasing returns - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

What analysts say about Protagonist Therapeutics Inc. stockHigh-performance investment picks - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Newport Daily News

Jul 24, 2025
pulisher
Jul 23, 2025

CEO’s Major Stock Sale Shakes Up Protagonist Therapeutics! - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

Protagonist Therapeutics CEO Patel sells $2.88 million in shares By Investing.com - Investing.com India

Jul 23, 2025
pulisher
Jul 23, 2025

Protagonist Therapeutics CEO Patel sells $2.88 million in shares - Investing.com

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Protagonist Therapeutics Inc. stock priceDynamic capital growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Is Protagonist Therapeutics Inc. a good long term investmentBreakout stock performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis - Lubbock Avalanche-Journal

Jul 22, 2025
pulisher
Jul 21, 2025

Polycythemia Vera Pipeline 2025: Latest FDA Approvals, - openPR.com

Jul 21, 2025
pulisher
Jul 21, 2025

Protagonist Announces Submission of NDA for First Icotrokinra U. - GuruFocus

Jul 21, 2025

Protagonist Therapeutics Inc (PTGX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$23.09
price down icon 1.32%
$37.06
price up icon 1.06%
$101.75
price down icon 2.12%
$27.45
price down icon 4.26%
$112.79
price down icon 2.19%
biotechnology ONC
$294.51
price up icon 1.04%
자본화:     |  볼륨(24시간):